The top names in diabetes research will be at TEDxDelMar in San Diego, discussing the future of diabetes care and cure. Want to be there?
ASweetLife, in conjunction with the organizing committee of the event, is giving away 10 free tickets to TEDxDelMar! So if you can be in San Diego on October 15, 2011 and would like to attend, send an email to TEDx@asweetlife.org, and we'll enter you in a drawing.
Following a review of new data from a 52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk’s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes...
The European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir, in children with type 1 diabetes, aged two to five years. The CHMP decision was made after the review of data demonstrating that insulin detemir...
Takeda Pharmaceutical announced the launch of LIOVEL®, a fixed dose combination tablet of NESINA® (alogliptin) and ACTOS® (pioglitazone HCl) for treatment of type 2 diabetes.
LIOVEL is a tablet taken orally once daily and has two dosage strengths
The UK-based company, Cellnovo, received CE Mark approval for the world’s first mobile diabetes management system, a significant milestone for the company and for people living with diabetes. Cellnovo is a complete diabetes management system built around the principles of mobile, wireless technology. The system includes an insulin patch pump, a wireless, touch screen handset with a built-in blood glucose monitor, and an extendable applications set...
Nick Jonas, of the Jonas Brothers, has teamed up with Bayer HealthCare for the “Simple Inspirations” contest. The contest, sponsored by Bayer HealthCare, challenges people living with diabetes to motivate newly diagnosed patients by sharing their most inspirational thoughts about living with the disease. The goal of the contest is to enrich the lives of everyone who has diabetes and to demonstrate that people with diabetes can live a full and engaged life by effectively managing their condition...
Results of an investigational Phase 3b clinical study, presented by Bristol-Myers Squibb Company and AstraZeneca at the 47th European Association for the Study of Diabetes (EASD), have shown that adding ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes...
Novo Nordisk's ultra-long-acting insulin degludec, an investigational basal insulin being developed, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon...
In a continued mission to reduce the global burden of noncommunicable diseases (NCDs) such as cardiovascular disease and diabetes Medtronic,…